Applicability and cost implications for proprotein convertase subtilisin/kexin type 9 inhibitors based on the odyssey outcomes trial

Authors

Salim S. Virani, Michael E. DeBakey Veterans Affairs Medical Center, USA.Follow
Julia M. Akeroyd, Michael E. DeBakey Veterans Affairs Medical Center, USA.
Vijay Nambi, Baylor College of Medicine, USA.
Erin D. Michos, Johns Hopkins University, USA.
Pamela B. Morris, Medical University of South Carolina, USA.
Khurram Nasir, Baptist Health South Florida, USA.
Sidney C. Smith Jr, University of North Carolina at Chapel Hill, USA.
Neil J. Stone, Northwestern University Feinberg School of Medicine, USA.
Laura A. Petersen, Michael E. DeBakey Veterans Affairs Medical Center, USA.
Christie M. Ballantyne, Baylor College of Medicine, USA.

Document Type

Article

Department

Office of the Provost; Cardiology

Comments

Abstract is not provided by the author/publisher. This work was published before the author joined Aga Khan University.

Publication (Name of Journal)

Circulation

DOI

10.1161/CIRCULATIONAHA.118.034993

Recommended Citation

Virani, S. S., Akeroyd, J. M., Nambi, V., Michos, E. D., Morris, P. B., Nasir, K., Smith, S. C., Stone, N. J., Petersen, L. A., Ballantyne, C. M. (2019). Applicability and cost implications for proprotein convertase subtilisin/kexin type 9 inhibitors based on the odyssey outcomes trial. Circulation, 139(3), 410-412.
Available at: https://ecommons.aku.edu/provost_office/668